skip to Cookie NoticeSkip to contents

Your health and safety remain our top priority: Learn about our Safe Care Commitment | Use our Prescreen app before arrival for faster entry | Read the COVID-19 Vaccine FAQs

Header Skipped.

Alzheimer’s Disease Drug Aduhelm

Information on the drug Aduhelm (aducanumab) for Alzheimer’s Disease

The Mass General Brigham (MGB) Center for Drug Policy is aware of interest in Aducanumab that was approved by the FDA on June 7th for the treatment of Alzheimer disease.

Click here to read the FDA announcement of approval

Like all other drugs used within the MGB system, Aducanumab will be subject to review by the MGB Pharmacy and Therapeutics Committee that is charged with evaluating and provide recommendations for the use of medications. The evaluation will include a review of clinical, economic, and operational considerations. This process, with the goal of ensuring safe and cost-effective use of medications within MGB, is expected to take 3-4 months. Additional information will be provided when it becomes available.


For over a century, a leader in patient care, medical education and research, with expertise in virtually every specialty of medicine and surgery.

About BWH